| User's Publication |
|
15892
Khorsandi SE, Dokal AD, Rajeeve V, Britton DJ, Illingworth MS, Heaton N, Cutillas PR.
Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
Cancer Res
2021
81(22):5765-5776
PubMed ID: 34551960
DOI: 10.1158/0008-5472.CAN-21-0955
|
|
13185
Pandey A, Stawiski EW, Durinck S, Gowda H, Goldstein LD, Barbhuiya MA, Schröder MS, Sreenivasamurthy SK, Kim SW, Phalke S, Suryamohan K, Lee K, Chakraborty P, Kode V, Shi X, Chatterjee A, Datta K, Khan AA, Subbannayya T, Wang J, Chaudhuri S, Gupta S, Shrivastav BR, Jaiswal BS, Poojary SS, Bhunia S, Garcia P, Bizama C, Rosa L, Kwon W, Kim H, Han Y, Yadav TD, Ramprasad VL, Chaudhuri A, Modrusan Z, Roa JC, Tiwari PK, Jang JY, Seshagiri S.
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Nat Commun
2020
PubMed ID: 32839463
DOI: 10.1038/s41467-020-17880-4
|
|
13336
Pan YR, Wu CE, Yeh CN.
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.
Biomolecules
2020
PubMed ID: 33182492
DOI: 10.3390/biom10111529
|
|
13778
Yamashita T, Kato K, Fujihara S, Iwama H, Morishita A, Yamana H, Kobayashi K, Kamada H, Chiyo T, Kobara H, Tsutsui K, Okano K, Suzuki Y, Masaki T.
Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest
Anticancer Drugs
2020
31(3):231-240
PubMed ID: 31815765
DOI: 10.1097/CAD.0000000000000870
|
|
20122
Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.
Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.
Front Immunol
2020
11:630139
PubMed ID: 33692777
DOI: 10.3389/fimmu.2020.630139
|
|
11395
Subbannayya T, Leal-Rojas P, Zhavoronkov A, Ozerov IV, Korzinkin M, Babu N, Radhakrishnan A, Chavan S, Raja R, Pinto SM, Patil AH, Barbhuiya MA, Kumar P, Guerrero-Preston R, Navani S, Tiwari PK, Kumar RV, Prasad TSK, Roa JC, Pandey A, Sidransky D, Gowda H, Izumchenko E, Chatterjee A.
PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40).
J Cell Commun Signal
2019
PubMed ID: 30666556
DOI: 10.1007/s12079-018-00503-5
|
|
11422
Hori R, Yamaguchi K, Sato H, Watanabe M, Tsutsumi K, Iwamoto S, Abe M, Onodera H, Nakamura S, Nakai R.
The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Cancer Med
2019
PubMed ID: 30735010
DOI: 10.1002/cam4.1949
|
|
3726
Kirti Gondkar, Krishna Patel, Geeta V. Patil Okaly, Bipin Nair, Akhilesh Pandey, Harsha Gowda and Prashant Kumar
Dickkopf Homolog 3 (DKK3) Acts as a Potential Tumor Suppressor in Gallbladder Cancer
Front Oncol
2019
9:1121
PubMed ID: 31737564
DOI: 10.3389/fonc.2019.01121
|
|
3737
Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Cells
2019
8(9):1026
PubMed ID: 31484399
DOI: 10.3390/cells8091026
|
|
3738
Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Cancer Chemother Pharmacol.
2019
83(4):659-671
PubMed ID: 30659304
DOI: 10.1007/s00280-019-03768-8
|
|
10759
Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Jpn. J. Clin. Oncol.
2018
48:396-399
PubMed ID: 29474549
DOI: 10.1093/jjco/hyy011
|
|
14913
Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
Dis Model Mech
2018
11(8):dmm03305
PubMed ID: 29666220
DOI: 10.1242/dmm.033050
|
|
10170
Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC.
Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Oncotarget
2017
8:26169-26184
PubMed ID: 28412732
DOI: 10.18632/oncotarget.15410
|
|
10222
Yang L, Huang S, Ma H, Wu X, Feng F.
MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer.
Tumour Biol.
2017
39:1010428317692249
PubMed ID: 28347246
DOI: 10.1177/1010428317692249
|
|
9533
Tadokoro T, Morishita A, Fujihara S, Iwama H, Niki T, Fujita K, Akashi E, Mimura S, Oura K, Sakamoto T, Nomura T, Tani J, Miyoshi H, Yoneyama H, Himoto T, Hirashima M, Masaki T.
Galectin-9: An anticancer molecule for gallbladder carcinoma.
Int. J. Oncol.
2016
48:1165-74
PubMed ID: 26797414
DOI: 10.3892/ijo.2016.3347
|
|
3729
Subbannayya T et al
Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.
BMC Cancer
2015
15:843
PubMed ID: 26530123
DOI: 10.1186/s12885-015-1855-z
|
|
3736
Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.
Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.
Mol Cancer Ther.
2015
14(9):1985-93
PubMed ID: 26141945
DOI: 10.1158/1535-7163.MCT-15-0069
|
|
13739
Letelier P, García P, Leal P, Álvarez H, Ili C, López J, Castillo J, Brebi P, Roa JC.
miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer
Int J Clin Exp Pathol
2014
7(5):1849-67
PubMed ID: 24966896
|
|
3715
Idrees AS, Sugie T, Inoue C, Murata-Hirai K, Okamura H, Morita CT, Minato N, Toi M, Tanaka Y.
Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Cancer Sci
2013
104(5):536-42
PubMed ID: 23387443
DOI: 10.1111/cas.12124
|
|
18721
Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Asahina D, Ushigome M, Hiraoka N, Nagino M, Kondo T.
Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma
J Proteomics
2012
75(5):1577-89
PubMed ID: 22155129
DOI: 10.1016/j.jprot.2011.11.030
|
|
7767
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
Br. J. Cancer
2011
105:131-8
PubMed ID: 21673683
DOI: 10.1038/bjc.2011.199
|
|
7862
Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J Hepatobiliary Pancreat Sci
2011
18:700-11
PubMed ID: 21451941
DOI: 10.1007/s00534-011-0376-7
|
|
13667
Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment
Cancer Sci
2010
101(4):882-8
PubMed ID: 20088962
DOI: 10.1111/j.1349-7006.2009.01462.x
|
|
3719
van Haaften G et al
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.
Nat Genet
2009
41(5):521-3
PubMed ID: 19330029
DOI: 10.1038/ng.349
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
|
18693
Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer
Gastroenterology
2008
135(4):1358-1368
PubMed ID: 18692501
DOI: 10.1053/j.gastro.2008.06.082
|
|
3717
Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, Chiba T.
Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.
Oncogene
2004
23(13):2401-7
PubMed ID: 14743205
DOI: 10.1038/sj.onc.1207395
|
Back
Top
CELL BANK Website
